| 摘要 |
The invention relates to exsulins or insulin mimetic amino acid sequences with a molecular weight of up to 55,000 daltons and with 1 to 50 basic units of following Formula (1): [-] L,V,I,A]-X<SUP>1</SUP>-X<SUP>2</SUP>-[L,V,I,A]-[D,E]-[N,Q,M]-X<SUB>3</SUB>-[C,H]-X<SUB>4 </SUB>[-], whereby; [L,V,I,A], [D,E], [N,Q,M], [C,H] and X<SUP>1 to 4 </SUP>represent peptidically linked amino acids; [L,V,I,A] represents leucine (L), valine (V), isoleucine (I) or alanine (A); [D,E] represents asparaginic acid (D) or glutamic acid (E); [N,Q,M] represents asparagine (N), glutamine (Q) or methionine (M); [C,H] represents cysteine (C) or histidine (H); both groups [L,V,I,A] in a basic unit can be identical or different; X<SUP>1</SUP>, X<SUP>2</SUP>, X<SUP>3 </SUP>and X<SUP>4 </SUP>represent any type of amino acid and the four amino acids X<SUP>1 to 4 </SUP>in a basic unit can be identical or different. The inventive exsulins can be used in dietetic and pharmaceutical agents, and to be precise, can be used for mimicking the properties and functions of members of the family of endogenous insulin and IGF proteohormones/mediators and for preventing, treating and influencing hormonal states and disturbances as well as various degenerative diseases of the body of mammals including various forms of hormonal metabolic disturbances, hormonal resistances, hormonal deficiencies, hyperinsulinemia, diabetes mellitus and autoimmune diseases as well as neurodegenerative and secondary diseases. |
